STAGES OF THE DEVELOPMENT OF OVARIAN CANCER SURGERY: LITERATURE REVIEW
- Authors: Kozhevnikova O.V.1, Nikogosyan S.O1, Kuznetsov V.V1, Ananyev V.S1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: Vol 23, No 2 (2018)
- Pages: 102-106
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/42982
- DOI: https://doi.org/10.18821/1028-9984-2018-23-2-102-106
- ID: 42982
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Olga V. Kozhevnikova
N.N. Blokhin National Medical Research Center of Oncology
Email: dr.kozhevnikova@mail.ru
MD, N.N. Blokhin National Medical Research Center of Oncology, Moscow, 115478, Russian Federation Moscow, 115478, Russian Federation
S. O Nikogosyan
N.N. Blokhin National Medical Research Center of OncologyMoscow, 115478, Russian Federation
V. V Kuznetsov
N.N. Blokhin National Medical Research Center of OncologyMoscow, 115478, Russian Federation
V. S Ananyev
N.N. Blokhin National Medical Research Center of OncologyMoscow, 115478, Russian Federation
References
- Rakhmatullina I.R., Khamitovа G.V., Khalikov L.V. Current realities and the possibility of surgical treatment of ovarian cancer. Meditsinskiy vestnik Bashkortostana. 2013; 8 (3): 117-23. (in Russian)/Рахматуллина И.Р., Хамитова Г.В., Халикова Л.В. Современные реалии и возможности хирургического лечения рака яичников. Медицинский вестник Башкортостана. 2013; 8 (3): 117-23.
- Zhordania K.I. Malignant ovarian neoplasms. In.: Encyclopedia of clinical Oncology. Moscow; 2004: 427-41. (in Russian)/Жорданиа К.И. Злокачественные новообразования яичников. В кн.: Энциклопедия клинической онкологии. М.: Издательская группа ГУ РОНЦ им. Н.Н. Блохина РАМН; 2004: 427-41.
- Bakrin N., Bereder J.M., Decullier E. et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur. J. Surg. Oncol. 2013; 39: 1435-43.
- Berretta R., Marchesi F., Volpi L, Ricotta G., Monica M. et al. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advancedovarian cancer: Clinical and functional outcome. Taiwan J. Obstet. Gynecol. 2016; 55(3): 346-50. doi: 10.1016/j.tjog.2016.04.010
- ESGO Ovarian Cancer Surgery Guidelines. European Society of Gynaecological Oncology. 2017; V. 2. guidelines.esgo.org
- Meigs J.V. Tumors of the Female Pelvic Organs. New York: Mac-Millan; 1934.
- Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl. Cancer Inst. Monogr. 1975; 42: 101-4. PMID: 1234624.
- Munnell E.W. The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am. J. Obstet. Gynecol. 1968; 100(6): 790-805. PMID: 4296050.
- Brinkhuis M., Baak J.P., Meijer G.A., van Diest P.J., Mogensen O. et al. Value of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma. J. Clin. Pathol. 1996; 49(2): 142-8.
- Sugarbaker P.H., Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann. Surg. Oncol. 1999; 6(8): 727-31.
- Chi D.S., Eisenhauer E.L., Zivanovic O. et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. 2009; 114(1): 26-31.
- Smith J.P., Day T.G. Review of ovarian cancer at the University of Texas, Systems Cancer Center MD Anderson Hospital and Tumor Institute. Am. J. Obstet. Gynecol. 1979; 135(7): 984-93. doi: 10.1016/0002-9378(79)90824-X
- Wharton T.J., Herson J. Surgery for common epithelial tumors of the ovary. Cancer. 1981; 48: 582-9.
- Heintz A.P.M., Hacker N.F., Berek J.S. et al. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet. Gynecol. 1986; 67: 783-8.
- Makar A.P., Baekelandt M., Tropé C.G., Kristensen G.B. The prognostic significance of residual disease, FIGO substage, tumor histo-logy, and grade in patients with FIGO stage III ovarian cancer. Gynecol. Oncol. 1995; 56(2): 175-80.
- Scarabelli C., Gallo A., Franceschi S., Campagnutta E., De Piero G., Giorda G. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000; 88: 389-97.
- Bristow R.E., del Carmen M.G., Kaufman H.S., Montz F.J. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J. Am. Coll. Surg. 2003; 197: 565-74.
- Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R. et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma? Gynecol. Oncol. 2006; 103 (2): 559-64. doi: 10.1016/j.ygyno.2006.03.051
- Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S. et al. Gynecologic Oncology Group Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Clin. Oncol. 2008; 26 (1): 83-9.
- Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. 2010. https://gogmember.org/manuals/pdf/surgman.pdf
- du Bois A., Reuss A., Pujade-Lauraine E. et al. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer. 2009; 115 (6): 1234-44.
- Vergote I., De Wever I., Tjalma W. et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol. Oncol. 1998; 71 (3): 431-6.
- Stoeckle E., Paravis P., Floquet A. et al. Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ova-rian cancer. Int. J. Gynecol. Cancer. 2004; 14: 779-87.
- Bristow R.E., Chang J., Ziogas A. et al. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival. J. Am. Coll. Surg. 2015; 220: 940-50.
- Bristow R.E., Chang J., Ziogas A. et al. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol. Oncol. 2014; 132: 403-10.
- Marszalek A., Alran S., Scholl S., Fourchotte V., Plancher C. et al. Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute. Int. J. Surg. Oncol. 2010; 2010: 214919. doi: 10.1155/2010/214919
- Di Giorgio A., Cardi M., Biacchi D., Sibio S. et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J. Surg. Oncol. 2013; 11: 64-72. doi: 10.1186/1477-7819-11-64
- Mandato V.D., Abrate M., De Iaco P., Pirillo D., Ciarlini G., et al. Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management. J. Ovarian Res. 2013; 6: 19-26. doi: 10.1186/1757-2215-6-19
- Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol. Oncol. 2006; 103 (3): 1083-90. Epub 2006 Aug 4.
- Shepherd J.H. The role of surgery in the management of ovarian cancer. Baillieres Clin. Obstet. Gynaecol. 1987; 1 (2): 353-67. PMID: 3319339
- Houvenaeghel G., Gutowski M., Buttarelli M., Cuisenier J., Narducci F. et al. Modified Posterior Pelvic Exenteration for Ovarian Cancer. Int. J. Gynecol. Cancer. 2009; 19 (5): 968-73. doi: 10.1111/IGC.0b013e3181a7f38b
- Arits A.H., Stoot J.E., Botterweck A.A. et al. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2008; 18: 621-8.
- Janco J.M., Glaser G., Kim B. et al. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol. Oncol. 2015; 138: 70-7.
- Vorgias G., Iavazzo C., Savvopoulos P. et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol. Oncol. 2009; 112: 11-5.
- Suidan R.S., Ramirez P.T., Sarasohn D.M. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 2014; 134: 455-61.